Recently, the Beijing Municipal Market Supervision and Administration Bureau investigated and dealt with the case of China Resources Zizhu Pharmaceutical Co., Ltd. reaching and implementing a monopoly agreement.

On May 24, the Beijing Municipal Market Supervision and Administration Bureau imposed administrative penalties on China Resources Zizhu Pharmaceutical Co., Ltd. for reaching and implementing a monopoly agreement of "fixing and limiting the price of Jinyuting and Yuting sold by dealers", ordering the parties to stop illegal activities, and a fine of 2% of its domestic sales in China in 2020 was imposed, RMB 12.6436 million in total.

The Beijing Municipal Market Supervision and Administration Bureau stated that the behavior of the parties violated the provisions of Article 14 (1) and (2) of the original "Anti-Monopoly Law of the People's Republic of China", it investigated and dealt with the case by the law, and corrected the violations. This case is the first case of anti-monopoly law enforcement in the field of pharmaceuticals in Beijing. Operators in the pharmaceutical industry shall abide by the concept of fair competition, attach great importance to the construction of anti-monopoly compliance, and avoid touching the red line of anti-monopoly laws.

From Zhichanqianyan

June 3rd, 2023